Scientists have identified nearly 200 genetic mutations in the SARS-CoV-2 that causes COVID-19 by analysing virus genes from over 7,500 people infected with the disease globally, an advance that offers clues to direct drugs and vaccine targets.
The study, published in the journal Infection, Genetics and Evolution, characterised patterns of diversity of the genome of the virus, highlighting how it may be adapting and evolving to its human hosts.
The researchers from University College London (UCL) in the UK found that a large proportion of the global genetic diversity of SARS-CoV-2 is found in all hardest-hit countries, suggesting extensive global transmission from early on in the epidemic and the absence of single ‘Patient Zeroes’ in most countries.
The findings further establish that the virus only emerged recently in late 2019, before quickly spreading across the globe.
The scientists identified 198 mutations that appear to have independently occurred more than once, which may hold clues to how the virus is adapting.
“All viruses naturally mutate. Mutations in themselves are not a bad thing and there is nothing to suggest SARS-CoV-2 is mutating faster or slower than expected,” Professor Francois Balloux from UCL said.
“So far we cannot say whether SARS-CoV-2 is becoming more or less lethal and contagious,” Balloux said.
The small genetic changes, or mutations, identified were not evenly distributed across the virus genome, the researchers said. As some parts of the genome had very few mutations, those invariant parts of the virus could be better targets for drug and vaccine development, they said. “A major challenge to defeating viruses is that a vaccine or drug might no longer be effective if the virus has mutated. If we focus our efforts on parts of the virus that are less likely to mutate, we have a better chance of developing drugs that will be effective in the long run,” Balloux explained.